Work

The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma

Year: 2018

Type: article

Abstract: The standard treatment for patients diagnosed with glioblastoma is surgical resection of tumor followed by high dose radiation and chemotherapy with temozolomide. For patients who experience allergic reactions to temozolomide despite desensitization protocols, alternative therapies must be considered. In this report, we present such a patient who then received treatment with an epidermal growth factor receptor inhibitor, erlotinib, concurrent with a tumor-treating field device, Optune. Through this combination of a targeted molecular therapy and the Optune device, the patient has been able to achieve stable disease 9 months after completing radiation.

Source: Oxford Medical Case Reports

DOI: 10.1093/omcr/omy095